<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Sat, 14 Feb 2026 06:35:12 +0000</lastBuildDate>
    <item>
      <title>#1 [90/100] Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41667463/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41667463/</guid>
      <dc:creator>Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, et al.</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üî• CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter, randomized phase 3 trial demonstrates non-inferior survival with a novel induction chemotherapy regimen in nasopharyngeal carcinoma, addressing significant treatment compliance issues and side effects associated with cisplatin. The long-term survival data and potential to change treatment practices elevate its impact.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature communications | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41467-026-69315-1'&gt;10.1038/s41467-026-69315-1&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41667463/'&gt;41667463&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;In nasopharyngeal carcinoma, cisplatin is known to be associated with poor treatment compliance and notable side effects. More effective and safer platinum drugs are needed for the treatment of patients with nasopharyngeal carcinoma. In 2021, our multicenter, randomized, phase 3 trial reported that lobaplatin and fluorouracil induction chemotherapy plus concurrent chemoradiotherapy resulted in non-inferior survival and fewer toxic effects than did cisplatin-based therapy in nasopharyngeal carcinoma. Data from the 10-year survival analysis are updated here. With a median follow-up of 10.6 years in the intention-to-treat population, 10-year progression-free survival is 70.7% in the lobaplatin-based therapy group vs. 71.9% in the cisplatin-based therapy group (HR 1.02, 95% CI 0.72-1.43; log-rank p‚Äâ=‚Äâ0.885). The difference between the groups is 1.2% (95% CI -6.7-9.1, pnon-inferiority‚Äâ=‚Äâ0.015), which is lower than the prespecified non-inferiority margin of 10%. The results are similar when we analyze patients in the per-protocol population. In the univariable and multivariable analyses, stage is an independent prognostic factor for progression-free survival (p‚Äâ=‚Äâ0.001). The subgroup analyses suggest that the non-inferiority of lobaplatin-based therapy did not differ among specific populations. The incidence of late toxic effects is similar between the therapy groups, except¬†for grades 1-2 peripheral neuropathy (p‚Äâ=‚Äâ0.033), grades 1-2 deafness/otitis (p‚Äâ=‚Äâ0.021), and grades 1-2/3 nephrotoxicity (p‚Äâ=‚Äâ0.005; p‚Äâ=‚Äâ0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.</description>
    </item>
    <item>
      <title>#2 [90/100] Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41667193/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41667193/</guid>
      <dc:creator>You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, et al.</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üî• CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicentre, randomized, open-label phase 3 trial evaluates the addition of camrelizumab to standard chemoradiotherapy in high-risk nasopharyngeal carcinoma, potentially offering significant clinical benefits and practice-changing findings in a high-impact area of oncology.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMJ (Clinical research ed.) | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1136/bmj-2025-085863'&gt;10.1136/bmj-2025-085863&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41667193/'&gt;41667193&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To assess treatment with camrelizumab (a programmed death 1 inhibitor) in addition to concurrent chemoradiotherapy and as a maintenance treatment in patients with high risk nasopharyngeal carcinoma. DESIGN: Multicentre, randomised, open label, phase 3 trial. SETTING: Seven hospitals in China between 18 August 2020 and 21 June 2022. PARTICIPANTS: Adults aged 18-70 years with newly diagnosed high risk nasopharyngeal carcinoma after three cycles of induction chemotherapy with gemcitabine and cisplatin (stage 4a, stage 2-3 with stable or progressive disease, or detectable Epstein-Barr virus DNA). INTERVENTIONS: Patients were randomly assigned (1:1) to receive combination chemoradiotherapy based on cisplatin (standard treatment group) or standard treatment with 19 cycles of intravenous camrelizumab (200 mg) once every three weeks (radiotherapy plus two concurrent cycles and 17 adjuvant cycles; camrelizumab group). MAIN OUTCOME MEASURES: The primary endpoint in the intention-to-treat group was progression-free survival, defined as the time from randomisation to disease recurrence (locoregional or distant) or death from any cause. Secondary endpoints included safety and overall survival. RESULTS: 390 patients were enrolled and randomly assigned to the camrelizumab group (n=194) or the standard treatment group (n=196). At median follow-up of 39.9 months (interquartile range 36.8-43.4 months), progression-free survival was higher in the camrelizumab group than the standard treatment group (36 months: 83.4%, 95% confidence interval 78.3% to 88.8% v 71.3%, 65.2% to 77.9%; stratified hazard ratio 0.51, 95% confidence interval 0.34 to 0.77, P=0.001). The incidence of acute and late adverse events (grade 3 or 4) was 50.5% and 3.2% in the camrelizumab group compared with 48.7% and 3.7% in the standard treatment group. Immunological adverse events (grade 3 or 4) occurred in 19 patients (10.2%) in the camrelizumab group. CONCLUSION: The addition of camrelizumab to concurrent chemoradiotherapy and as a maintenance treatment improved progression-free survival among patients with high risk nasopharyngeal carcinoma after induction chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04453826.</description>
    </item>
    <item>
      <title>#3 [75/100] Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41671524/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41671524/</guid>
      <dc:creator>Xiang J, Geiger JL</dc:creator>
      <pubDate>Wed, 11 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses insights from a significant study (LEAP-010) in recurrent/metastatic head and neck cancer, likely providing important clinical implications and novel insights, but it is not a primary research article itself.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Xiang J, Geiger JL&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of clinical oncology : official journal of the American Society of Clinical Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1200/JCO-25-02640'&gt;10.1200/JCO-25-02640&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-11&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41671524/'&gt;41671524&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#4 [75/100] A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C).</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41672251/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41672251/</guid>
      <dc:creator>Tawk B, Halec G, Rein K, Schwager C, Knoll M, Wirkner U, Held T, Weykamp F, Liermann J, Hoerner-Rieber J, et al.</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The study validates a tumor DNA methylation signature in a multicenter cohort of HPV-negative HNSCC patients, providing important insights into predicting distant metastasis after postoperative radiochemotherapy, which has potential clinical implications.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Tawk B, Halec G, Rein K, Schwager C, Knoll M, Wirkner U, Held T, Weykamp F, Liermann J, Hoerner-Rieber J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2026.111433'&gt;10.1016/j.radonc.2026.111433&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41672251/'&gt;41672251&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND AND PURPOSE: Tumor hypoxia is a predictive biomarker of treatment resistance in patients with head and neck squamous cell carcinoma (HNSCC). We previously reported the discovery of a tumor DNA methylation signature of hypoxia (Hypoxia-M), identifying HNSCC patients at risk for local recurrence (LR), all event progression, and death after primary radiochemotherapy (RCHT). We further validate Hypoxia-M in an independent cohort of HNSCC patients who underwent surgical resection followed by postoperative radiochemotherapy (PORT-C) METHODS: Hypoxia-M was validated in HPV-negative HNSCC patients (n‚ÄØ=‚ÄØ134) homogeneously treated with PORT-C in the frame of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) multicenter biomarker trial. DNA methylation was profiled using Illumina450K technology. The performance of Hypoxia-M was integrated with previously reported biomarkers, including gene expression signatures (GES) of hypoxia, a methylome-based HPV-Independent Classifier of disease Recurrence (HICR), and immune cell score using immunohistochemistry (CD3/CD8/PD-L1/PD1). RESULTS: Hypoxia-M was independently prognostic for overall survival (OS, HR‚ÄØ=‚ÄØ2.34, p‚ÄØ=‚ÄØ0.03) and distant metastasis (DM, HR‚ÄØ=‚ÄØ4.3, p‚ÄØ=‚ÄØ0.001), but not for LR after PORT-C. Hypoxia-M remained significant after adjusting for patient≈õ age, gender, smoking status, tumor stage, and high-risk features (ECE&amp;/R1 resection). Hypoxia-M status was inversely associated with CD8 T-cell infiltration. Patient stratification improved by integrating previously reported biomarkers, with Hypoxia-M demonstrating independent prognostic performance. CONCLUSIONS: The prognostic utility of Hypoxia-M was validated in an independent cohort. Our results highlighted a difference in recurrence patterns of hypoxic tumors treated in the primary setting (local recurrence) versus postoperatively (distant metastasis) and the utility of Hypoxia-M for identifying the main pattern of recurrence.</description>
    </item>
    <item>
      <title>#5 [75/100] Androgen Receptor Signaling Induces CD8‚Å∫ T Cell Dysfunction that is Reversed by Androgen Deprivation Therapy in Male Head and Neck Squamous Cell Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41661680/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41661680/</guid>
      <dc:creator>Wang Q, Tan Z, Zheng C, Xu J, Li Q, Hong S, Yu D, Hu X, Wang J, Jiang L, et al.</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study identifies a novel mechanism by which androgen receptor signaling affects CD8‚Å∫ T cell function in HNSCC, with implications for androgen deprivation therapy; while it presents important findings, it is based on a single study rather than a large-scale trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Wang Q, Tan Z, Zheng C, Xu J, Li Q, Hong S, Yu D, Hu X, Wang J, Jiang L, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Cancer research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/0008-5472.CAN-25-2384'&gt;10.1158/0008-5472.CAN-25-2384&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41661680/'&gt;41661680&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Head and neck squamous cell carcinoma (HNSCC) exhibits a distinct sex disparity in incidence, with a higher incidence in males than females. Recent studies have suggested that this difference persists even after accounting for smoking and alcohol use, highlighting the need to elucidate the underlying biological mechanisms. In this study, we demonstrated that sex differences in HNSCC are androgen-dependent and identified androgen receptor (AR) signaling as a key regulator of the tumor immune microenvironment by modulating CD8‚Å∫ T cell differentiation and function. Mechanically, early growth response 4 (EGR4) functioned as a direct downstream transcriptional effector of AR that induced CD8‚Å∫ T cell dysfunction. Clinically, androgen deprivation therapy (ADT) was an effective therapeutic strategy in HNSCC, suppressing tumor growth in mice while improving intratumoral CD8‚Å∫ T cell function. Moreover, combining ADT with immune checkpoint inhibitors led to improved antitumor efficacy. Together, these findings reveal ADT as a promising therapeutic approach to enhance the antitumor activity of sex-biased CD8‚Å∫ T cells in HNSCC, which could inform the development of sex-biased immunotherapies for treating HNSCC patients.</description>
    </item>
    <item>
      <title>#6 [75/100] Prognostic significance of extranodal extension in cervical lymph node metastases of head and neck squamous cell carcinoma: A systematic review and meta-analysis with bibliometric overview.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41655423/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41655423/</guid>
      <dc:creator>Singh SP, Prasad S, Dean PM, Kujur AL, Jaiswal G</dc:creator>
      <pubDate>Sat, 07 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis addresses an important prognostic factor in head and neck squamous cell carcinoma, providing valuable insights into survival impact and global research trends, which could influence clinical practice.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Singh SP, Prasad S, Dean PM, Kujur AL, Jaiswal G&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107862'&gt;10.1016/j.oraloncology.2026.107862&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-07&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41655423/'&gt;41655423&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: Extranodal extension (ENE) of cervical lymph node metastases is a key prognostic factor in head and neck squamous cell carcinoma (HNSCC). This systematic review and meta-analysis evaluated the survival impact of ENE in HNSCC and identified global research trends relevant to this research field through a complementary bibliometric analysis. MATERIALS AND METHODS: ScienceDirect, PubMed, and Scopus were systematically searched during 2000-2025. A systematic review and a meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. A Scopus-based bibliometric analysis was conducted using the Biblioshiny package of R to identify and map the publication trends, influential authors, and major institutional contributions between 2010 and 2025. RESULTS: Of the 839 retrieved records, 711 studies were screened, and 16 studies comprising approximately 3900 patients met all inclusion criteria. The bibliometric analysis of 120 Scopus-indexed publications demonstrated a marked increase in ENE-related research from 2015 onward, driven primarily by institutions in Australia, Taiwan, and South Korea. Keyword mapping indicated expanding intersections of ENE research with radiomics, prognostic modelling, and refinement of staging systems. Meta-analysis confirmed a significant association between ENE and adverse survival outcomes. Subgroup analyses showed consistently poor prognostic implications across both pathologic and radiologic ENE assessments. CONCLUSION: ENE in cervical lymph node metastases is an independent and strong predictor of adverse survival in HNSCC. The increasing global attention to ENE highlights its crucial role in multidisciplinary oncologic management. Therefore, standardized pathological and imaging-based assessment of ENE is essential for developing superior prognostic models and optimizing future treatment planning strategies.</description>
    </item>
    <item>
      <title>#7 [70/100] Proposed Version Nine of the AJCC and UICC TNM Classification for Salivary Gland Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41678147/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41678147/</guid>
      <dc:creator>Huang SH, Cotler J, Palis B, Seethala RR, Hosni A, O'Sullivan B, Vander Poorten V, Bishop JA, Glastonbury CM, Beadle B, et al.</dc:creator>
      <pubDate>Thu, 12 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study proposes a novel pTNM classification for salivary gland carcinoma, which could enhance prognostic accuracy and clinical decision-making, but it is a retrospective analysis rather than a randomized controlled trial or large prospective study.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Huang SH, Cotler J, Palis B, Seethala RR, Hosni A, O'Sullivan B, Vander Poorten V, Bishop JA, Glastonbury CM, Beadle B, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.5396'&gt;10.1001/jamaoto.2025.5396&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41678147/'&gt;41678147&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: A unified salivary gland carcinoma (SGC)-specific tumor-node-metastasis (TNM) classification can enhance prognostic accuracy, support clinical decision-making, and improve the quality of patient care. OBJECTIVE: To derive and validate an SGC-specific pTNM classification with improved prognostic accuracy and optimized stage distribution for version nine of the American Joint Committee on Cancer/Union for International Cancer Control staging protocol. DESIGN, SETTING, AND PARTICIPANTS: This retrospective prognostic cohort study derived a novel pTNM classification using data from the National Cancer Database (NCDB) of patients with surgically treated major SGC (2012-2017) and validated it in an international major SGC cohort (2008-2021) and a single-institution minor SGC cohort (Memorial Sloan Kettering Cancer Center; 1985-2016). Data were analyzed from June to November 2024. EXPOSURES: Surgery with or without postoperative radiotherapy or chemoradiotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Cox proportional hazards multivariable analysis was used to confirm the prognostic importance of pathologically positive lymph node (LN) number and extranodal extension (pENE) and derive an optimal pTNM classification. RESULTS: The NCDB dataset included 8409 patients with SGC: 7659 with M0 disease (5748 with pN0 disease and 1911 with pN+ disease) and 750 with M1 disease. Among the 7659 patients with M0 disease, the median (IQR) age was 60 (48-71) years, and 3861 (50.4%) were male. The median (IQR) follow-up was 88.4 (72.3-108.5) months. The 5-year OS was 87.2% (95% CI, 86.3-88.0) for N0 disease, 68.2% (95% CI, 63.9-72.8) for 1 positive LN without pENE, 60.2% (95% CI, 53.5-67.5) for 2 positive LNs without pENE, 68.4% (95% CI, 58.0-76.6) for 3 positive LNs without pENE, 47.5% (95% CI, 41.6-52.8) for more than 3 positive LNs without pENE, and 41.4% (38.1-44.8) for pENE-positive LNs. Multivariable analysis confirmed the independent prognostication of LN count compared with pN0 disease (1 positive LN: adjusted hazard ratio [aHR], 1.70; 95% CI, 1.44-2.01; 2 positive LNs: aHR, 1.61; 95% CI, 1.31-1.98; 3 positive LNs: aHR, 2.10; 95% CI, 1.65-2.68; 4 positive LNs : aHR, 2.46; 95% CI, 1.87-3.24; more than 4 positive LNs: aHR, 2.07; 95% CI, 2.08-2.91) and pENE-positive LNs compared with pENE-negative LNs (aHR, 1.27; 95% CI, 1.10-1.48). The proposed pN classification were pN1 for 1 to 3 positive LNs and pENE negativity and pN2 for more than 3 positive LNs or pENE positivity. Model fit improved with the proposed pN classification vs the current pN classification (Akaike Information Criterion, 26‚ÄØ442 vs 26‚ÄØ483). Based on the aHR model, the following stage groups were proposed: stage I: T1N0 (1 [reference]); stage II: T2N0 (aHR, 1.34; 95% CI, 1.11-1.61); stage IIIA: T1-2N1 or T3-4N0 (aHR, 2.36; 95% CI, 1.99-2.80); stage IIIB: T1-2N2 or T3-4N1-2 (aHR, 5.15; 95% CI, 4.38-6.06); and stage IV: M1 disease (aHR, 13.61; 95% CI, 11.37-16.29). The C index values were similar (proposed classification: 0.792; current classification: 0.790), while the AIC improved slightly (proposed classification: 26‚ÄØ441; current classification: 26‚ÄØ482). Stage-specific OS differences were evident in both the international major SGC cohort (n‚Äâ=‚Äâ1015) and Memorial Sloan Kettering Cancer Center minor SGC cohort (n‚Äâ=‚Äâ444). CONCLUSIONS AND RELEVANCE: This unified, SGC-specific staging system improved prognostic accuracy and sample size balance and was applicable to both major and minor SGCs.</description>
    </item>
    <item>
      <title>#8 [70/100] The impact of tobacco cessation on buccal mucosa cancer risk: A multi-centre case-control study in India.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41657059/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41657059/</guid>
      <dc:creator>Pullat GB, Bohrmann B, George GS, Dikshit S, Singh A, Chaturvedi P, Dikshit R, Lewington S, Mhatre S</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multi-centre case-control study with a large sample size provides important insights into the effects of tobacco cessation on buccal mucosa cancer risk, which has significant clinical implications, although it is not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Pullat GB, Bohrmann B, George GS, Dikshit S, Singh A, Chaturvedi P, Dikshit R, Lewington S, Mhatre S&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ijc.70372'&gt;10.1002/ijc.70372&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41657059/'&gt;41657059&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;While the association between tobacco consumption and oral cancer is well established, the effect of tobacco cessation, particularly chewing tobacco, is less extensively studied. We aim to explore the effect of tobacco cessation on the risk of buccal mucosa cancer (BMC). A case-control study was conducted across five cancer centres in India. We enrolled 2320 BMC and 2302 frequency-matched controls. Information was collected on smoking and chewing (products, duration and quitting). Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) of the effect of tobacco cessation compared to current users, after adjusting for potential confounders. For both smoking and chewing, the odds reduced rapidly after 5‚Äâyears of quitting, so that those who had quit smoking ‚â•10‚Äâyears ago had only 0.39 (95% CI 0.28-0.54) the odds of BMC compared to those who continued to smoke, and those who quit chewing ‚â•10‚Äâyears ago had 0.58 (95% CI 0.43-0.81) the odds of BMC compared to those who continued to chew. Chewing with areca nut was associated with almost double the risk of chewing without (OR 1.86, 95% CI 1.53-2.26) but the rate of reduction of risk with quitting was similar. These findings show clearly the benefits of quitting and inform policies that emphasize chewing tobacco cessation, given its widespread prevalence in India.</description>
    </item>
    <item>
      <title>#9 [65/100] Laryngeal Chondrosarcoma: A SEER Database Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41685670/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41685670/</guid>
      <dc:creator>Bhalerao RV, Huppert Steed A, Kelbert J, Hintze JM, Lott DG, Jategaonkar AA</dc:creator>
      <pubDate>Fri, 13 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study utilizes a large dataset from the SEER database to analyze a rare tumor, providing important insights into treatment trends and survival outcomes, but it is a retrospective analysis without novel therapeutic implications.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Bhalerao RV, Huppert Steed A, Kelbert J, Hintze JM, Lott DG, Jategaonkar AA&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; The Laryngoscope | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/lary.70442'&gt;10.1002/lary.70442&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-13&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41685670/'&gt;41685670&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVES: Laryngeal chondrosarcoma (LC) is a rare tumor accounting for less than 1% of all laryngeal cancers. While surgery is the primary treatment, national trends in management and outcomes remain poorly defined. This study aimed to analyze incidence, survival, and treatment strategies for LC using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: Patients with LC diagnosed between 2000 and 2021 were identified from SEER. Demographic, treatment, and survival data were analyzed. Kaplan-Meier analysis and multivariate Cox regression were used to analyze survival outcomes. RESULTS: In total, 351 patients with LC were identified, representing 0.3% of all laryngeal malignancies. Among patients with treatment data, 53.3% underwent local excision or partial laryngectomy, 27.5% underwent total laryngectomy (TL), and 19.2% received no surgery. Ten-year disease-specific survival was 84.8%. Patients undergoing partial resection demonstrated significantly improved survival compared with TL (p‚Äâ&lt;‚Äâ0.05), although this finding is likely confounded by tumor size and stage. On multivariate analysis, advanced stage (HR 2.59, 95% CI 1.68-3.97), older age (HR 1.66, 95% CI 1.36-1.99), and TL (HR 2.95, 95% CI 1.88-4.62) were associated with worse survival. CONCLUSION: LC remains rare but carries favorable long-term survival. National trends demonstrate a shift toward organ-preserving surgery, with partial resections increasingly favored over TL. Prognosis is most strongly influenced by age and stage, while radiation therapy appears to play a little role. These findings support organ preservation in appropriately selected patients and highlight the need for prospective studies integrating oncologic and functional outcomes.</description>
    </item>
    <item>
      <title>#10 [65/100] Does the site of origin of mucoepidermoid carcinoma impact treatment outcomes? Long-term analysis of 244 patients over a decade.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41680505/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41680505/</guid>
      <dc:creator>Panda S, Chettuvatti K, Kumar R, Thakar A, Sikka K, Singh CA, Kumar R, Sood R, Salam TA, Kaur K, et al.</dc:creator>
      <pubDate>Thu, 12 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study analyzes a substantial cohort of 244 patients with mucoepidermoid carcinoma, providing important insights into prognostic factors; however, it is a retrospective analysis and does not present novel therapeutic findings or practice-changing implications.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Panda S, Chettuvatti K, Kumar R, Thakar A, Sikka K, Singh CA, Kumar R, Sood R, Salam TA, Kaur K, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1007/s00405-026-10031-3'&gt;10.1007/s00405-026-10031-3&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41680505/'&gt;41680505&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Mucoepidermoid carcinoma (MEC) is the most common malignant histology encountered in salivary glands. Due to the rarity of salivary gland malignancies and more than 20 different histological types, there is a need to analyse clinicopathological risk factors of each histology separately, with emphasis on long-term outcomes. METHODS: Retrospective cohort study from a tertiary care centre conducted from 2014 to 2024 on all histologically confirmed MEC that underwent upfront surgery. RESULTS: 244 MEC [major salivary gland (MASG)-153, minor salivary gland (MISG)-91] were available for analysis. The median follow-up was 39 months. Location in MISG, higher T category and female sex were independent prognostic variables for survival on multivariate analysis (MVA) of the entire cohort. The impact of tumour location persisted following matched-pair analysis controlling for tumour stage, grade and margin status (OS: HR:5.3, 95% CI: 2.1 to 12.9; DFS: HR: 2.7, 95% CI: 1.2 to 5.8). The predominant pattern of failure for tumour located in MISG was distant metastasis, whereas in MASG, loco-regional failure was commonly encountered. In terms of tumour grade, low-grade and high-grade had the best and worst outcomes for both MASG and MISG. However, survival curves for intermediate-grade tumours clustered with low-grade tumours in MASG and with high-grade tumours in MISG. CONCLUSION: Tumour location demonstrated a pronounced impact on MEC outcomes following treatment, independent of AJCC staging and histological grade.</description>
    </item>
  </channel>
</rss>
